Glepaglutide (acetate)

Glepaglutide (ZP1848) acetate, a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide acetate reduces faecal output and increases intestinal absorption. Glepaglutide acetate alleviates small intestinal inflammation. Glepaglutide acetate can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease[1][2][3].

Product Specifications

Product Name Alternative

ZP1848 (acetate)

UNSPSC

12352209

Target

GCGR

Type

Peptides

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/glepaglutide-acetate.html

Purity

99.92

Solubility

H2O : ≥ 50 mg/mL

Smiles

[HGEGTFSSELATILDALAARDFIAWLIATKITDKKKKKK-NH2]

Molecular Formula

C199H329N53O57

Molecular Weight

4376.06

References & Citations

[1]Naimi RM, et al. a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial. Lancet Gastroenterol Hepatol. 2019 May;4 (5) :354-363. |[2]Janssen P, et al. Review article: a comparison of glucagon-like peptides 1 and 2. Aliment Pharmacol Ther. 2013 Jan;37 (1) :18-36. |[3]Jolanta Skarbaliene, et al. ZP1848, a Novel GLP-2 Agonist, Provides a Wide Window of Therapeutic Efficacy in the Experimental Crohn's Disease Model. Gastroenterology, 2011, 140 (5) : S519.